drugset / Trial / NCT06100237
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
Timeline
- Start
- 2023-12-04
- Primary completion
- 2028-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Talquetamab | Monoclonal antibody | — | — |
| Subject | Teclistamab | Monoclonal antibody | — | Subcutaneous |